Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript
Source: SeekingAlpha
2026-03-10 14:30:26 ET
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension March 10, 2026 12:00 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript
Galectin Therapeutics Inc.
NASDAQ: GALT
GALT Trading
-2.52% G/L:
$3.09 Last:
133,571 Volume:
$3.15 Open:
GALT Latest News
February 26, 2026 04:05:00 pm
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
January 19, 2026 12:32:00 am
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
January 14, 2026 09:51:00 am
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors
December 29, 2025 09:54:00 pm
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
GALT Stock Data
$183,102,729
30,560,103
0.23%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
NORCROSS
